Cytokinetics, Incorporated

CYTK

$65.44

Name : Cytokinetics, Incorporated

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $8,001,017,344.00

EPSttm : -6.3

Cytokinetics, Incorporated

$65.44

2.04%

$1.36

Float Short %

11.1

Margin Of Safety %

Put/Call OI Ratio

0.18

EPS Next Q Diff

0.01

EPS Last/This Y

-0.83

EPS This/Next Y

0.02

Price

66.77

Target Price

89.94

Analyst Recom

1.43

Performance Q

7.4

Relative Volume

1.02

Beta

0.55

Ticker: CYTK

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-13	CYTK	63.29	0.17	0.03	127226
2026-01-14	CYTK	64.56	0.17	0.06	130251
2026-01-15	CYTK	63.43	0.17	0.40	129170
2026-01-16	CYTK	62.57	0.17	0.30	129537
2026-01-20	CYTK	63.78	0.13	0.40	71501
2026-01-21	CYTK	63.06	0.14	1.36	72406
2026-01-22	CYTK	64.9	0.14	0.67	72660
2026-01-23	CYTK	63.44	0.14	0.79	73339
2026-01-26	CYTK	63.18	0.15	0.21	73917
2026-01-27	CYTK	63.97	0.15	0.40	75184
2026-01-28	CYTK	65.14	0.15	0.18	76100
2026-01-29	CYTK	65.57	0.15	0.12	76541
2026-01-30	CYTK	63.25	0.15	0.45	76784
2026-02-02	CYTK	65.14	0.15	0.09	77542
2026-02-03	CYTK	64.83	0.15	1.19	77676
2026-02-05	CYTK	60.26	0.16	1.18	78576
2026-02-09	CYTK	63.36	0.18	0.25	81335
2026-02-10	CYTK	64.82	0.19	0.01	81427
2026-02-11	CYTK	66.62	0.18	0.17	83847
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-13	CYTK	63.31	-7.3	150.5	-6.09
2026-01-14	CYTK	64.57	-7.3	130.4	-6.09
2026-01-15	CYTK	63.42	-7.3	149.1	-6.09
2026-01-16	CYTK	62.59	-7.3	146.9	-6.09
2026-01-20	CYTK	63.80	-7.3	130.4	-6.09
2026-01-21	CYTK	63.05	-7.3	145.9	-6.09
2026-01-22	CYTK	64.87	-7.3	-35.5	-6.09
2026-01-23	CYTK	63.43	-7.3	-1.3	-6.09
2026-01-26	CYTK	63.16	-8.5	-13.8	-6.09
2026-01-27	CYTK	63.99	-8.5	-24.6	-6.09
2026-01-28	CYTK	65.21	-8.5	-28.7	-6.09
2026-01-29	CYTK	65.63	-8.5	-21.4	-6.09
2026-01-30	CYTK	63.20	-8.5	7.4	-6.09
2026-02-02	CYTK	65.12	-8.5	-36.1	-6.09
2026-02-03	CYTK	64.74	-8.5	-12.2	-6.09
2026-02-04	CYTK	63.53	-8.5	-3.5	-6.09
2026-02-05	CYTK	60.21	-8.5	17.6	-6.09
2026-02-06	CYTK	62.33	-8.5	-39.0	-6.09
2026-02-09	CYTK	63.35	-8.5	-26.9	-6.09
2026-02-10	CYTK	64.83	-8.5	-31.7	-6.09
2026-02-11	CYTK	66.77	-8.5	-35.7	-6.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-13	CYTK	-8.83	3.36	11.54
2026-01-14	CYTK	-8.83	3.36	11.54
2026-01-15	CYTK	-8.83	3.36	11.54
2026-01-16	CYTK	-8.66	3.36	11.54
2026-01-20	CYTK	-8.66	2.94	11.54
2026-01-21	CYTK	-8.66	2.94	11.54
2026-01-22	CYTK	-8.66	2.94	11.54
2026-01-23	CYTK	-8.66	2.94	11.54
2026-01-26	CYTK	-8.59	2.40	11.54
2026-01-27	CYTK	-8.59	2.40	11.54
2026-01-28	CYTK	-8.59	2.40	11.17
2026-01-29	CYTK	-8.59	2.40	11.17
2026-01-30	CYTK	-8.59	2.40	11.17
2026-02-02	CYTK	-8.44	2.18	11.17
2026-02-03	CYTK	-8.44	2.18	11.17
2026-02-04	CYTK	-8.44	2.18	11.17
2026-02-05	CYTK	-8.44	2.18	11.17
2026-02-06	CYTK	-8.90	2.18	11.17
2026-02-09	CYTK	-8.90	2.85	11.17
2026-02-10	CYTK	-8.90	2.85	11.17
2026-02-11	CYTK	-8.90	2.85	11.10
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-1.54

Avg. EPS Est. Current Quarter

-1.35

Avg. EPS Est. Next Quarter

-1.53

Insider Transactions

-8.9

Institutional Transactions

2.85

Beta

0.55

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

39.4

Max Drawdown 5-Year %

-72.4

Target Price

89.94

P/E

Forward P/E

PEG

P/S

93.65

P/B

P/Free Cash Flow

EPS

-6.31

Average EPS Est. Cur. Y

-6.09

EPS Next Y. (Est.)

-6.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-862.21

Relative Volume

1.02

Return on Equity vs Sector %

116.4

Return on Equity vs Industry %

132.8

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.19

EBIT Estimation

-35.7

Cytokinetics, Incorporated

Sector: Healthcare

Industry: Biotechnology

Employees: 498

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today

news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance

stock history CYTK – Cytokinetics, Incorporated invest stock market

stock prices CYTK premarket after hours

ticker CYTK fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CYTK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y